Cart
sales@molnova.com
Tribuloside
CAS No. 22153-44-2
Tribuloside( —— )
Catalog No. M18252 CAS No. 22153-44-2
A new cinnamolyglycoflavonoid 3-cinnamoyltribuloside, its precursor tribuloside and two known flavonoid glycosides afzelin and astilbin were isolated from Heritiera littoralis Dryand (Sterculiaceae) ethanolic leaf extract.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 158 | In Stock |
|
| 5MG | 117 | In Stock |
|
| 10MG | 188 | In Stock |
|
| 25MG | 330 | In Stock |
|
| 50MG | 479 | In Stock |
|
| 100MG | 682 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTribuloside
-
NoteResearch use only, not for human use.
-
Brief DescriptionA new cinnamolyglycoflavonoid 3-cinnamoyltribuloside, its precursor tribuloside and two known flavonoid glycosides afzelin and astilbin were isolated from Heritiera littoralis Dryand (Sterculiaceae) ethanolic leaf extract.
-
DescriptionA new cinnamolyglycoflavonoid 3-cinnamoyltribuloside, its precursor tribuloside and two known flavonoid glycosides afzelin and astilbin were isolated from Heritiera littoralis Dryand (Sterculiaceae) ethanolic leaf extract.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetAntibacterial
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number22153-44-2
-
Formula Weight594.52
-
Molecular FormulaC30H26O13
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (210.25 mM)
-
SMILESO=c1c(O[C@@H]2O[C@@H]([C@@H](O)[C@H](O)[C@H]2O)COC(=O)/C=C/c2ccc(O)cc2)c(oc2cc(O)cc(O)c12)c1ccc(O)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Christopher R, et al. Nat Prod Res. 2014;28(6):351-8.
molnova catalog
related products
-
HMPC
HMPC is a novel bacteriostatic agent that shows bacteriostatic activity against S. aureus (MIC=4?μg/ml) and rescues Caenorhabditis elegans from S. aureus infection.
-
Durlobactam
Durlobactam is a novel beta-lactamase inhibitor for treatment of resistant bacterial infections.
-
GSK-2140944
GSK-2140944 (Gepotidacin) is a novel potent, selective bacterial type II topoisomerase inhibitor in development for the treatment of conventional and biothreat pathogens.
